Company OPKO Health, Inc.

Equities

OPK

US68375N1037

Healthcare Facilities & Services

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Ratings for OPKO Health, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical & Diagnostic Laboratories

Real-time Estimate Cboe BZX Other stock markets 20:28:01 03/05/2024 BST			5-day change	1st Jan Change
1.295 ^USD	-0.38%		+2.78%	-14.24%

03-28	Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	MT
03-20	Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	CI

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.

Number of employees: 3,930

USD in Million	2022	Weight	2023	Weight	Delta
Diagnostics 59.7 %	756	75.2 %	515	59.7 %	-31.81%
Pharmaceutical 40.3 %	249	24.8 %	348	40.3 %	+40.09%

USD in Million	2022	Weight	2023	Weight	Delta
United States 69.2 %	783	78.0 %	598	69.2 %	-23.67%
Ireland 16.4 %	117	11.7 %	141	16.4 %	+20.69%
Chile 7.9 %	62	6.2 %	68	7.9 %	+10.39%
Spain 2.7 %	22	2.2 %	24	2.7 %	+4.63%
Mexico 2.3 %	15	1.4 %	20	2.3 %	+38.98%
Israel 1.1 %	4	0.4 %	10	1.1 %	+153.26%
Other 0.3 %	1	0.1 %	2	0.3 %	+160.25%

Managers	Title	Age	Since
Phillip Frost CEO	Chief Executive Officer	87	26/03/07
Adam Logal DFI	Director of Finance/CFO	46	28/02/07
Elias Zerhouni PSD	President	72	08/05/22
Elizabeth Nabel CTO	Chief Tech/Sci/R&D Officer	72	30/04/22
Jane Hsaio CTO	Chief Tech/Sci/R&D Officer	77	31/01/07
Steven Rubin ADM	Chief Administrative Officer	63	31/01/07
Gary Nabel BRD	Director/Board Member	70	08/05/22
Jane Pine Wood LAW	General Counsel	-	-
Stephen A. Strugnell PRN	Corporate Officer/Principal	-	08/04/14

Members of the board	Title	Age	Since
Phillip Frost CEO	Chief Executive Officer	87	26/03/07
Roger Medel BRD	Director/Board Member	77	17/12/20
Richard Pfenniger BRD	Director/Board Member	68	31/12/07
Steven Rubin ADM	Chief Administrative Officer	63	31/01/07
Lin-Tsing Yu BRD	Director/Board Member	80	22/04/09
Jane Hsaio CTO	Chief Tech/Sci/R&D Officer	77	31/01/07
John Paganelli BRD	Director/Board Member	89	30/11/03
Richard Krasno BRD	Director/Board Member	82	08/02/17
Elias Zerhouni PSD	President	72	08/05/22
Gary Nabel BRD	Director/Board Member	70	08/05/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	705,646,759	331,723,053 ( 47.01 %)	8,655,082 ( 1.227 %)	47.01 %

Name	Equities	%	Valuation
Phillip Frost 35.03 %	244,164,353	35.03 %	293 M $
Elias Zerhouni 5.846 %	40,745,228	5.846 %	49 M $
Vanguard Fiduciary Trust Co. 5.703 %	39,751,293	5.703 %	48 M $
The Vanguard Group, Inc. 5.703 %	39,751,293	5.703 %	48 M $
BlackRock Advisors LLC 4.958 %	34,559,815	4.958 %	41 M $
Jane Hsaio 4.753 %	33,127,284	4.753 %	40 M $
Gary Nabel 2.945 %	20,526,980	2.945 %	25 M $
Elizabeth Nabel 2.857 %	19,912,459	2.857 %	24 M $
Geode Capital Management LLC 1.394 %	9,719,368	1.394 %	12 M $
STATE STREET CORPORATION 1.335 %	9,306,684	1.335 %	11 M $

Name	Equities	%	Valuation
GENEDX HOLDINGS CORP. 13.66%	3,558,601	13.66%	32,490,027 $

OPKO Health, Inc.

4400 Biscayne Boulevard

33137, Miami

+305 575 4100

http://www.opko.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.3 USD

Average target price

4.25 USD

Spread / Average Target

+226.92%

Consensus

Estimates Revisions

Company calendar

Healthcare

Healthcare Services

Healthcare Providers & Services

Healthcare Facilities & Services

Medical & Diagnostic Laboratories

	1st Jan change	Capi.
OPKO HEALTH, INC.	-14.24%	906M
SONIC HEALTHCARE LIMITED	-18.58%	8.15B
RADNET, INC.	+48.06%	3.82B
SYNLAB AG	-8.58%	2.47B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-38.71%	2.46B
DR. LAL PATHLABS LIMITED	-10.06%	2.34B
NEOGENOMICS, INC.	-6.00%	1.88B
FLEURY S.A.	-17.24%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.78%	1.21B
METROPOLIS HEALTHCARE LIMITED	+6.69%	1.11B

Medical & Diagnostic Laboratories